Lucy Scientific Discovery

Lucy Scientific Discovery is positioning itself at the intersection of neuroscience and psychedelic medicine, aiming to develop and commercialize new therapeutic entities. The company leverages its status as a licensed dealer of controlled substances to conduct research and provide CRO services. Its strategic direction involves building a pipeline of proprietary drug candidates while generating early revenue through its contract research capabilities. As a public company, it seeks to capitalize on the growing investment and regulatory interest in psychedelic-assisted therapies.

Regulatory platform based on Health Canada Controlled Drugs and Substances Dealer's Licenses, enabling research, development, and CRO services for psychedelic and psychotropic compounds.

Total raised: $6M

Lucy faces competition from advanced clinical-stage biotechs like COMPASS Pathways and MAPS PBC, as well as other early-stage psychedelic drug developers. Its differentiation lies in its hybrid CRO/drug development model and its foundational Health Canada licenses, though it operates with significantly less capital and later-stage assets than its main competitors.